Ropes & Gray Advises Bain Capital Life Sciences in Convertible Preferred PIPE Investment

In The News
April 14, 2017

Ropes & Gray represented Bain Capital Life Sciences, Bain’s new life sciences fund, in its recent convertible preferred PIPE investment in Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics. Bain Capital Life Sciences led a syndicate of current and new investors in the stock purchase.  Dicerna intends to use the proceeds from the $70 million preferred stock offering to further develop its GalXC™ pipeline programs.  The transaction closed on April 12.

The Ropes & Gray team was led by life sciences partner Michael Beauvais and securities & public companies associates Tom Fraser (both of Boston), and included securities & public companies partner Joel Freedman (Boston), life sciences partner Al Cacozza (Washington, D.C.), tax partner Pamela Glazier (New York), securities & public companies associate Ray Grant and life sciences associate Raj Banerjee (both of Boston).